Literature DB >> 22530737

Antibiotic prophylaxis in the era of multidrug-resistant bacteria.

Bastiaan H J Wittekamp1, Marc J M Bonten.   

Abstract

The prophylactic use of antibiotics can only be justified when clinical benefits on relevant patient outcomes, such as morbidity or mortality, cost-effectiveness, and absence of immediate emergence of antibiotic resistance have been unequivocally demonstrated. In some intensive care unit (ICU) patients, antibiotic prophylaxis is used as part of selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD). Recent trials in ICUs with low levels of antibiotic resistance strongly suggest that both regimens reduce the incidence of ICU-acquired infections and improve patient survival. Naturally, the unique microbial ecology of such settings reduce generalizability of results. Therefore, the routine use of SOD and SDD remains highly controversial, especially in ICUs with higher levels of antibiotic resistance. Moreover, convincing evidence is still missing on several important aspects related to efficacy and safety. Despite numerous trials, effects of SDD and SOD on antibiotic resistance during and after decolonization treatment have still been insufficiently investigated, and existing results are contradicting. Furthermore, the effects of both regimens on the non-culturable part of the intestinal flora remain unknown. Finally, cost-effectiveness has not been thoroughly investigated, and prices of the antimicrobial agents that have been used have increased dramatically in recent years. In this review, important knowledge gaps that so far prevent the widespread use of SDD and SOD will be addressed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22530737     DOI: 10.1517/13543784.2012.681642

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  3 in total

1.  Control of colonisation with extended-spectrum β-lactamase-producing bacteria: reply to Zandstra et al.

Authors:  Christian Brun-Buisson; Keyvan Razazi; Lennie P G Derde; Marc J M Bonten
Journal:  Intensive Care Med       Date:  2013-01-04       Impact factor: 17.440

2.  Pediatric infectious diseases: getting research evidence into practice and generation of new evidence.

Authors:  Hans Van Rostenberghe
Journal:  Front Pediatr       Date:  2014-12-08       Impact factor: 3.418

3.  Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens.

Authors:  Shin Young Hyun; Sang Hoon Han; Soo-Jeong Kim; Ji Eun Jang; Yundeok Kim; Hyunsoo Cho; Jung Yeon Lee; June-Won Cheong; Yoo Hong Min; Jae-Woo Song; Jin Seok Kim
Journal:  J Korean Med Sci       Date:  2016-02-22       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.